Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature
- PMID: 26967162
- PMCID: PMC4788143
- DOI: 10.1371/journal.pone.0151632
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature
Abstract
Observational studies have demonstrated that metformin use in diabetic patients is associated with reduced cancer incidence and mortality. Here, we aimed to determine whether metformin use was associated with improved survival in patients with resected pancreatic cancer. All patients with diabetes who underwent resection for pancreatic adenocarcinoma between 12/1/1986 and 4/30/2013 at our institution were categorized by metformin use. Survival analysis was done using the Kaplan-Meier method, with log-rank test and Cox proportional hazards multivariable regression models. For analyses of our data and the only other published study, we used Meta-Analysis version 2.2. We identified 44 pancreatic cancer patients with diabetes who underwent resection of the primary tumor (19 with ongoing metformin use, 25 never used metformin). There were no significant differences in major clinical and demographic characteristics between metformin and non-metformin users. Metformin users had a better median survival than nonusers, but the difference was not statistically significant (35.3 versus 20.2 months; P = 0.3875). The estimated 2-, 3-, and 5-year survival rates for non-metformin users were 42%, 28%, and 14%, respectively. Metformin users fared better with corresponding rates of 68%, 34%, and 34%, respectively. In our literature review, which included 111 patients from the two studies (46 metformin users and 65 non-users), overall hazard ratio was 0.668 (95% CI 0.397-1.125), with P = 0.129. Metformin use was associated with improved survival outcomes in patients with resected pancreatic cancer, but the difference was not statistically significant. The potential benefit of metformin should be investigated in adequately powered prospective studies.
Conflict of interest statement
Figures
Similar articles
-
Metformin use is associated with better survival of diabetic patients with pancreatic cancer.Clin Cancer Res. 2012 May 15;18(10):2905-12. doi: 10.1158/1078-0432.CCR-11-2994. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465831 Free PMC article.
-
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.J Clin Oncol. 2016 Jun 1;34(16):1898-904. doi: 10.1200/JCO.2015.63.3511. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069086 Free PMC article.
-
Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea.Oncotarget. 2017 Feb 7;8(6):9587-9596. doi: 10.18632/oncotarget.14525. Oncotarget. 2017. PMID: 28077783 Free PMC article.
-
Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis.Cell Physiol Biochem. 2018;49(3):837-847. doi: 10.1159/000493214. Epub 2018 Sep 5. Cell Physiol Biochem. 2018. PMID: 30184547 Review.
-
Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.Curr Med Chem. 2018;25(22):2595-2607. doi: 10.2174/0929867324666170412145232. Curr Med Chem. 2018. PMID: 28403788 Free PMC article. Review.
Cited by
-
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.J Cancer Res Clin Oncol. 2016 Oct;142(10):2159-71. doi: 10.1007/s00432-016-2178-4. Epub 2016 May 9. J Cancer Res Clin Oncol. 2016. PMID: 27160287 Review.
-
ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma.Ann Surg Oncol. 2021 Apr;28(4):2323-2324. doi: 10.1245/s10434-020-09139-5. Epub 2020 Sep 14. Ann Surg Oncol. 2021. PMID: 32929602 No abstract available.
-
Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: A meta-analysis.Mol Clin Oncol. 2018 Mar;8(3):483-488. doi: 10.3892/mco.2017.1541. Epub 2017 Dec 20. Mol Clin Oncol. 2018. PMID: 29468063 Free PMC article.
-
Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin.Cancer Manag Res. 2018 Jul 13;10:2003-2018. doi: 10.2147/CMAR.S161824. eCollection 2018. Cancer Manag Res. 2018. PMID: 30034255 Free PMC article. Review.
-
Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors.Front Oncol. 2019 Sep 20;9:902. doi: 10.3389/fonc.2019.00902. eCollection 2019. Front Oncol. 2019. PMID: 31616628 Free PMC article. No abstract available.
References
-
- American Cancer Society (2014) Cancer Facts and Figures. Atlanta, GA: American Cancer Society.
-
- Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254–258. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical